



INTRODUCING Pr **pms-ABIRATERONE**

A generic equivalent to ZYTIGA®
in the treatment of metastatic
prostate cancer



Demonstrated
bioequivalent
to ZYTIGA®



Available in
two doses:
250 and 500 mg



Brand-similar patient
support program to ensure
a smooth transition

pms-ABIRATERONE is indicated in combination with prednisone for the treatment of metastatic prostate cancer (castration-resistant prostate cancer, mCRPC) in patients who:

- are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy
- have received prior chemotherapy containing docetaxel after failure of androgen deprivation therapy


pms-ABIRATERONE is also indicated in combination with prednisone and androgen deprivation therapy (ADT) for the treatment of patients with newly diagnosed hormone-sensitive high-risk metastatic prostate cancer who may have received up to 3 months of prior ADT.^{1,2}




EQUIVALENT EFFICACY AND SAFETY PROFILE TO ZYTIGA®

pms-ABIRATERONE is bioequivalent to the Canadian reference product ZYTIGA®¹

LINEAR PROFILE OF THE MEAN: pms-ABIRATERONE 250 mg vs. ZYTIGA® 250 mg*³



LINEAR PROFILE OF THE MEAN: pms-ABIRATERONE 500 mg vs. ZYTIGA® 500 mg†³



SIMILAR APPEARANCE TO BRAND VERSION TO HELP TRANSITION YOUR PATIENTS‡



For visual comparison only, not actual size.

pms-ABIRATERONE OFFERS THE SAME BENEFITS OF THE BRAND VERSION—BUT AT A LOWER COST:

-  Same safety profile as brand
-  Same efficacy as brand
-  Lower cost

PRODUCT NAME	FORMAT	UPC	DIN
pms-ABIRATERONE 250 mg	Bottle of 120 tabs	0 57606 00798 8	02492601
pms-ABIRATERONE 500 mg	Bottle of 60 tabs	0 57606 00800 8	02501503

*Mean of 69 subjects.

†Studied under fasting conditions. Untransformed data.

‡For illustrative purposes only. No clinical benefit suggested.



THE ALLY PATIENT SUPPORT PROGRAM

Brand-similar reimbursement support for you and your patients

The Ally program is dedicated to supporting you and your patients.

Ally offers financial assistance and clinical and specialty nursing coordination similar to brand.

KEY PROGRAM FEATURES:



Financial assistance

Support for access to treatment when starting on pms-ABIRATERONE for eligible patients.



Reimbursement support

The **Ally Program** helps patients navigate coverage with their payer.



Bimonthly blood tests*

Coordination of bloodwork appointments

Ongoing support*

Bimonthly phone calls from a nurse for the first three months to support your patients.

Response to **patient general information calls**.

Simple enrolment process

Complete the one-page enrolment and consent form with your patient (by hand or as an editable PDF) and **fax it to 1-833-255-9544 or email it to ally@patientassistance.ca**.

QUESTIONS? WE ARE HERE TO HELP.



Call us at 1-833-ALLY100
(1-833-255-9100) or



Email the editable PDF to
ally@patientassistance.ca

*For treatment-naive patients only.

FOR YOUR PATIENTS WITH mCRPC, MAKE THE SWITCH TO pms-ABIRATERONE

Demonstrated bioequivalent to the Canadian reference product ZYTIGA®¹

Consult the Product Monograph for important information about:

- Contraindications in patients who are hypersensitive to the drug or any ingredient in the formulation or component of the container.
- The most serious warnings and precautions regarding hypertension, hypokalemia, and fluid retention due to mineralocorticoid excess; use in patients with a history of cardiovascular disease or moderate and severe hepatic impairment; and hepatotoxicity, including fatal cases.
- Other relevant warnings and precautions regarding use with gonadotropin-releasing hormone agonists or patients with previous orchiectomy treatment; taking on an empty stomach; reproductive toxicology; carcinogenesis and mutagenesis; corticosteroid withdrawal and stress; hepatic impairment; use with chemotherapy or radium 223 dichloride; skeletal muscle effects.
- Conditions of clinical use, adverse reactions, drug interactions, and dosing instructions.

The Product Monograph is also available through our medical department. Call us at 1-888-550-6060.

References:

1. ^Ppms-ABIRATERONE (abiraterone acetate uncoated tablets, 250 mg) Product Monograph. Pharmascience Inc. September 25, 2019.
2. ^Ppms-ABIRATERONE (abiraterone acetate film-coated tablets, 500 mg) Product Monograph. Pharmascience Inc. July 2, 2020.
3. Data on file. Pharmascience Inc.

© 2020 Pharmascience Inc.

6111 Royalmount Avenue
Montreal, Quebec
H4P 2T4 Canada
Phone: 1-800-340-9735